****

**M-ERA.NET Call 2023**

**Full-Proposal**

***Project Acronym:***

***Project Coordinator:***

***(Organisation and Country):***

**Each partner is requested to contact the respective national/regional funding organisation before Full-Proposal submission**

*To be submitted by the Project Coordinator only.*

*The Full-Proposal form has a technical limit of 40 pages.*

*Refer to Guide for Proposers when filling out this form.*

***The following formatting conditions apply:***

*The minimum font size should be 11 points. Standard character spacing and a minimum of single line spacing is to be used. Text elements other than the body text, such as headers, foot/end notes, captions, formulas, may deviate, but must be legible. The page size is A4, and all margins (top, bottom, left, right) should be at least 15 mm (not including any footers or headers).*

***Attention:***

*The structure, the order of chapters and the formatting conditions of the proposal form must not be changed. Any restructuring and change of the proposal form will result in a formal rejection of the proposal.*

**Content**

[1. SUMMARY 3](#_Toc127870703)

[2. CONSORTIUM OVERVIEW Attention: PIC is Mandatory 5](#_Toc127870704)

[3. EXCELLENCE 6](#_Toc127870705)

[3.1 Objectives of the project and expected results 6](#_Toc127870706)

[3.2 Concept and approach 6](#_Toc127870707)

[3.3 Ambition 6](#_Toc127870708)

[4. IMPACT 7](#_Toc127870709)

[4.1 Contribution at the European or international level to the expected impacts listed under the selected call topic 7](#_Toc127870710)

[4.2 Significance of the project results and user benefit 7](#_Toc127870711)

[4.3 Sustainability and RRI 7](#_Toc127870712)

[4.4 Dissemination and exploitation strategy 8](#_Toc127870713)

[4.4.1 Management of intellectual property rights (IPR) 8](#_Toc127870714)

[4.4.2 Dissemination activities of project results 8](#_Toc127870715)

[4.4.3 Plans for the commercialisation of results 8](#_Toc127870716)

[4.4.4 Management of research data 8](#_Toc127870717)

[5. IMPLEMENTATION 9](#_Toc127870718)

[5.1 Work plan 9](#_Toc127870719)

[5.1.1 Overview 9](#_Toc127870720)

[5.1.2 Detailed description of work package 9](#_Toc127870721)

[5.1.3 Time schedule 9](#_Toc127870722)

[5.2 Management structure and procedures 10](#_Toc127870723)

[5.3 Quality of the individual participants 10](#_Toc127870724)

[5.4 Consortium as a whole 10](#_Toc127870725)

[5.5 Cost calculation and resources 11](#_Toc127870726)

[5.5.1 Personnel cost 11](#_Toc127870727)

[5.5.2 Equipment 11](#_Toc127870728)

[5.5.3 Consumables 11](#_Toc127870729)

[5.5.4 Travel 11](#_Toc127870730)

[5.5.5 Subcontracting 11](#_Toc127870731)

[5.5.6 Other costs (i.e. for seminars, etc) 12](#_Toc127870732)

[5.5.7 Indirect costs 12](#_Toc127870733)

[6. ETHICAL ISSUES 14](#_Toc127870734)

[7. CHECKLIST FOR PROPOSERS 15](#_Toc127870735)

*Colour Code:*

*Black: text in black must be kept*

*Blue: text in blue is for information purpose and can be deleted.*

# 1. SUMMARY

|  |  |
| --- | --- |
| **Project Acronym**  |       |
| **Proposal Long Title**  |       |
| **Project Coordinator** | Name: |       |
| E-mail: |       |
| Coordinator Organisation(full name in original language / name in English) | Original Language:       English:       | Country/ Region |       |
| Address |       | Tel: |       |
| Fax: |       |
| Postal code (CEDEX)  |       |
| City |       | www: |       |
| **Total Project Costs****(Euro)** |       | **Requested Funding** **(Euro)**  |       |
| Planned starting date  |       | Duration (in months) |       | Total person months |       |
| Call Topic | [ ]  | Sustainable advanced materials for energy |
| [ ]  | Innovative surfaces, coatings and interfaces |
| [ ]  | High performance composites |
| [ ]  | Functional materials |
| [ ]  | Advanced materials and technologies for health applications |
| [ ]  | Next generation materials for advanced electronics |

**Publishable Abstract**

***Publishable Abstract for funded projects, including:*** *specific innovation objectives and results, needs addressed, impact and potential benefits (up to 1000 characters)*

*Please use these headlines for structuring the publishable abstract*

* Rationale / Needs to be addressed
* Objectives
* Potential applications
* Impact and potential benefits

**Publishable Contact Details**

I agree that the coordinators contact details (name and e-mail address) will be published

Yes [ ]

No [ ]

**Project Summary**

***Project Summary, including:*** *specific innovation objectives and results, needs addressed, impact and potential benefits (up to 4000 characters).
Whenever appropriate, indicate the TRL[[1]](#footnote-1) position in the beginning of the project and after the project is finished (not mandatory).*

# 2. CONSORTIUM OVERVIEW Attention: PIC is Mandatory

|  |
| --- |
| **CONSORTIUM OVERVIEW** |
| **Organisation** | **Partner name (Full name)** | **Coordinator (P1)** | **Partner 2:** | **Partner 3:** | **Partner 4:** | **Partner 5:** |
| **Participation Identification Code (PIC) [[2]](#footnote-2)** |  |  |  |  |  |
| TRL[[3]](#footnote-3) at project start |  |  |  |  |  |
| TRL at project end |  |  |  |  |  |
| Organisation Type[[4]](#footnote-4) |  |  |  |  |  |
| Website http: |  |  |  |  |  |
| Region / Country |  |  |  |  |  |
| Organisation registration number[[5]](#footnote-5) |  |  |  |  |  |
| Size (Employees) [[6]](#footnote-6) |  |  |  |  |  |
| Turnover (K€) 6 |  |  |  |  |  |
| **Contact Person** | Title / Name |  |  |  |  |  |
| Telephone |  |  |  |  |  |
| E-mail |  |  |  |  |  |
| **Funding Organisation (FO)** | Name of FO +Contact person in in FO [[7]](#footnote-7) |  |  |  |  |  |
| Funding Programme (full name[[8]](#footnote-8)) |  |  |  |  |  |

# 3. EXCELLENCE

*Describe the innovation of the project outcome(s), the originality of the proposed approach and the market needs (if applicable) addressed by the project. Please indicate the TRL at the start and at the end of the project.*

## 3.1 Objectives of the project and expected results

## 3.2 Concept and approach

* *Overall concept*
* *Start and target TRL*
* *Approach to Responsible Research & Innovation*

## 3.3 Ambition

* *Current state of the art and progress beyond the state of the art*
* *Originality and/or innovation of the proposed approach*
* *Key results of the project and innovation potential*

# 4. IMPACT

## 4.1 Contribution at the European or international level to the expected impacts listed under the selected call topic

*Describe for each partner the expected results and impact (internal benefits for partners), including market impact if applicable:*

* **Scientific impacts**

* **Economic impacts** *(for low TRLs present the visions for potential industrial use)*

## 4.2 Significance of the project results and user benefit

*Describe for each partner the strategic significance and external benefits of the project results in qualitative and quantitative terms.*

* *Innovation capacity and integration of new knowledge*
* *Competitiveness and growth of companies (market analysis where relevant)*

## 4.3 Sustainability and RRI

*Explain how the project will engage with:*

* *circularity, environmental dimensions of the proposed research*
* *ethical, political, social and/or cultural dimensions of the proposed research*
* *Please describe the gender relevance of your topic[[9]](#footnote-9) (if relevant) and the gender balance of the project consortium*

## 4.4 Dissemination and exploitation strategy

*Describe for each partner measures to disseminate and exploit the project results and to maximise the impact.*

## 4.4.1 Management of intellectual property rights (IPR)

## 4.4.2 Dissemination activities of project results

## 4.4.3 Plans for the commercialisation of results

*(for high TRL: present the visions for potential industrial use)***:**

**Partner 1 (Coordinator):**

**Partner 2:**

**Partner 3:**

*Please duplicate as needed*

## 4.4.4 Management of research data

*(where relevant)*

# 5. IMPLEMENTATION

## 5.1 Work plan

## 5.1.1 Overview

*Describe briefly the overall structure of the work plan.*

**Table: Work package list**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **WP no.** | **Work package title** | **Work package leader** | **Participating project partners** | **Start [month]** | **End [month]** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |

## 5.1.2 Detailed description of work package

*Describe the content of the individual work packages.*

*Please duplicate for each work package.*

|  |  |
| --- | --- |
| **WP number**: |  |
| **WP title**:  |  |
| **Leader**:  |  |
| **Partners involved**: |  |
| **Start date**: |  |
| **End date**: |  |
| **Objectives**:  |  |
| **Type of activities:** | *Research activity on TRL basis: development, demonstration etc. (according to national funding rules for each partner)* |
| **Description of content:** | *Activities, different tasks and methods including who is responsible, involved etc.* |
| **Milestones:** |  |
| **Expected results and deliverables**: | *For each partner* |

## 5.1.3 Time schedule

*Describe the timing of the different work packages and their components.*

*Please provide a clearly arranged and detailed time schedule (Gantt chart).*

## 5.2 Management structure and procedures

*Describe the organisational structure and the decision-making.*

## 5.3 Quality of the individual participants

*Describe briefly the role and expertise of each partner team in the project. Explain the added value expected from the transnational cooperation for each partner.*

*Please use “Annex 1 to the Full-Proposal” for detailed partner descriptions and CVs. This document has no page limitation.*

**Partner 1 (Coordinator):**

**Role in the project**:

**Relevant expertise**:

**Added value:**

**Partner 2:**

**Role in the project:**

**Relevant expertise**:

**Added value:**

**Partner 3:**

**Role in the project:**

**Relevant expertise**:

**Added value:**

*Please duplicate as needed*

## 5.4 Consortium as a whole

* **Complementarity and balance of the consortium including gender aspects**

* **Inter- and transdisciplinarity character of the consortium**

*If an interdisciplinary approach is not taken, please justify the decision here.*

## 5.5 Cost calculation and resources

*Describe the relevance of the items listed in the table for total project costs in accordance to relevant national/regional eligibility rules and justify the resources to be committed for each partner.*

*Please list explicitly any direct costs (5.5.1 – 5.5.6) and indirect costs (5.5.7).*

## 5.5.1 Personnel cost

**Partner 1 (Coordinator):**

**Partner 2:**

**Partner 3:**

*Please duplicate as needed*

## 5.5.2 Equipment

**Partner 1 (Coordinator):**

**Partner 2:**

**Partner 3:**

*Please duplicate as needed*

## 5.5.3 Consumables

**Partner 1 (Coordinator):**

**Partner 2:**

**Partner 3:**

*Please duplicate as needed*

## 5.5.4 Travel

**Partner 1 (Coordinator):**

**Partner 2:**

**Partner 3:**

*Please duplicate as needed*

## 5.5.5 Subcontracting

**Partner 1 (Coordinator):**

**Partner 2:**

**Partner 3:**

*Please duplicate as needed*

## 5.5.6 Other costs (i.e. for seminars, etc)

**Partner 1 (Coordinator):**

**Partner 2:**

**Partner 3:**

*Please duplicate as needed*

## 5.5.7 Indirect costs

**Partner 1 (Coordinator):**

**Partner 2:**

**Partner 3:**

*Please duplicate as needed*

**Table: Total project costs (only integer)**

*Describe costs of all project partners in EURO.*

*Please refer to eligible costs for each partner at national/regional level. For Total Costs each category must be filled in the first line and for Requested Funding must be filled in the second line according to specific national/regional rules.*

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Partner** | **Person months** | **Personnel cost** | **Equipment** | **Consum-ables** | **Travel** | **Sub-contracting** | **Other costs** | **Indirect** **costs** | **Total** **costs** | **Total requested funding** |
|  | **Euro** | **Euro** | **Euro** | **Euro** | **Euro** | **Euro** | **Euro** | **Euro** | **Euro** |
| Partner 1 (Coordinator) |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| Partner 2: |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| Partner 3: |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| Partner 4: |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| Partner 5: |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| **Total:** |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |

# 6. ETHICAL ISSUES

*Please fill YES or NO.*

| **ETHICAL ISSUES[[10]](#footnote-10)** | **YES / NO** | **Page** |
| --- | --- | --- |
| **HUMAN EMBRYOS/FOETUSES** |
| Does your research involve Human Embryonic Stem Cells (hESCs)? |  |  |
| Does your research involve the use of human embryos? |  |  |
| **HUMANS** |
| Does your research involve human participants? |  |  |
| Does this activity involve interventions (physical also including imaging technology, behavioural treatments, etc.) on the study participants? |  |  |
| Does this activity involve conducting a clinical study as defined by the Clinical Trial Regulation (EU 536/2014[[11]](#footnote-11))? (using pharmaceuticals, biologicals, radiopharmaceuticals, or advanced therapy medicinal products) |  |  |
| **HUMAN CELLS / TISSUES** (not covered by section 1) |
| Does your research involve human cells or tissues? |  |  |
| **PERSONAL DATA** |
| Does your research involve processing of personal data? |  |  |
| Does it involve the processing of special categories of personal data (e.g. sexual lifestyle, ethnicity, genetic, biometric and health data, political opinion, religious or philosophical beliefs)? |  |  |
| If YES | Does it involve processing of genetic, biometric or health data? |  |  |
| Does it involve profiling, systematic monitoring of individuals, or processing of large scale of special categories of data or intrusive methods of data processing (such as, surveillance, geolocation tracking etc.)? |  |  |
| Does this activity involve further processing of previously collected personal data (including use of pre-existing data sets or sources, merging existing data sets)? |  |  |
| **ANIMALS** |
| Does your research involve animals? |  |  |
| **ENVIRONMENT, HEALTH and SAFETY** |
| Does this activity involve the use of substances or processes that may cause harm to the environment, to animals or plants (during the implementation of the activity or further to the use of the results, as a possible impact)? |  |  |
| Does this activity deal with endangered fauna and/or flora / protected areas? |  |  |
| Does this activity involve the use of substances or processes that may cause harm to humans, including those performing the activity (during the implementation of the activity or further to the use of the results, as a possible impact)? |  |  |
| **ARTIFICIAL INTELLIGENCE**  |
| Does this activity involve the development, deployment and/or use of Artificial Intelligence?  |  |  |
| **OTHER ETHICS ISSUES**  |
| Are there any other ethical issues that should be taken into consideration?  |  |  |
| *Please specify (max. 1000 characters)* |  |  |

|  |  |
| --- | --- |
| **I CONFIRM that I have taken into account all ethics issues above.**  | [ ]  |

# 7. CHECKLIST FOR PROPOSERS (must not be deleted)

|  |  |
| --- | --- |
| The proposal conforms to the call guidelines. | [ ]  |
| Every project partner has been in direct contact with his/her national / regional funding agency and has checked that their collaboration and their project contributions are eligible for funding. | [ ]  |
| All project partners have checked the national/regional programme procedures and regulations. All project partners are aware of documents requested by the national/regional funding organisations.***IMPORTANT REMINDER: All consortium partners must check if applications (at Pre-Proposal and/or Full-Proposal stage) have to be submitted also to their national/regional funding organisations.*** | [ ]  |
| All partners who are not eligible for 100% funding are able to provide financial resources for their own contribution. | [ ]  |
| The consortium is aware that a duly signed and stamped consortium agreement (CA) between the project partners is recommended for funded projects based on national/regional funding rules, including agreements on intellectual property rights (IPR) and agreements on scientific publications. At the time of proposal submission it is recommended to provide the principles ruling the CA but not the CA itself. | [ ]  |

***Please go to*** [***https://www.m-era.net/joint-call-2023***](https://www.m-era.net/joint-call-2023) ***to submit this Full-Proposal form and the Annex 1 to the Full-Proposal form online.***

***Deadline for submission: 21November 2023, 12:00 noon Brussels time***

***For further information on M-ERA.NET, please go to:*** [***http://www.m-era.net***](http://www.m-era.net)

1. TRL: Technology Readiness Level; <https://ec.europa.eu/research/participants/data/ref/h2020/other/wp/2018-2020/annexes/h2020-wp1820-annex-g-trl_en.pdf> [↑](#footnote-ref-1)
2. Insert Participant Identification Code (PIC) of your organisation as used for participating on Horizon Europe. Information on how to find / get your PIC see FAQs on the Call page. [↑](#footnote-ref-2)
3. Technology Readiness Level (see Annex 2 in the Guide for Proposers) [↑](#footnote-ref-3)
4. HE-University, RES-Research organisation, SME-Small and Medium sized Enterprise, IND-Large Company, OTH-Others. (according to national rules) [↑](#footnote-ref-4)
5. VAT number or other Registration number [↑](#footnote-ref-5)
6. Only for companies [↑](#footnote-ref-6)
7. **It is strongly recommended to contact M-ERA.NET contact person in your region/country** for further information about funding rules, prior to the submission of a Full-Proposal (see [Participating countries & regions Call 2023](https://www.m-era.net/joint-call-2023/participating-countries-regions-call-2023) ) [↑](#footnote-ref-7)
8. Name of the funding programme for which the partner is applying [↑](#footnote-ref-8)
9. *Please note that this question does not refer to gender balance in the teams in charge of carrying out the project but to the content of the planned research and innovation activities. Sex and Gender analysis refers to biological characteristics and social/cultural factors respectively.
See factsheet: European Commission, Directorate-General for Research and Innovation, Gendered innovations : how inclusive analysis contributes to research and innovation, Publications Office, 2020,* [*https://data.europa.eu/doi/10.2777/361142*](https://data.europa.eu/doi/10.2777/361142) [↑](#footnote-ref-9)
10. Table assembled based on EC Horizon Europe Guidance: <https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/how-to-complete-your-ethics-self-assessment_en.pdf> [↑](#footnote-ref-10)
11. <https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32014R0536> [↑](#footnote-ref-11)